We thus questioned classical activators of VEGFR3 such as VEGFC and VEGFD, which can be secreted by aggressive tumor cells and play key roles in neolymphangiogenesis in cancer (Karaman & Detmar, 2014; Stacker et al, 2014). This evidence concerns the gene FLT4 and cancer.